GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sinew Pharma 6634.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

56.70

+2.16%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Sinew Pharma

Its shares trade on Taipei Exchange under the ticker 6634.TWO. It has been listed since 29 June 2017. In the fiscal year to 31 December 2025, it reported revenue of TWD 47,000 and a net loss of TWD 123.7m. At that date it held total assets of TWD 1.13bn and shareholders' equity of TWD 1.09bn.

Sinew Pharma, Inc. engages in the research and development of drugs related to liver disease treatment and pain treatment. The company is headquartered in Taipei City, Taipei. The company went IPO on 2017-06-29. The firm primarily focus on the research and development of liver disease treatment drugs and pain medication. The firm's main products include fatty liver disease treatment drugs SNP-610, SNP-630, no hepatotoxicity painkillers SNP-810 and antidote SNP-820. The firm's products are in clinical trials.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
29 Jun 2017
Employees
49

Leadership

Pay as last reported

  • Kaimin ZhuChairman of the Board, General Manager
  • Zhenghui XiongDeputy General Manager, Chief Research & Development Officer, Director
  • Ziwen ChenHead of Finance & Accounting
  • Mr. Han-Pin KuoDirector
  • Xuanzhe LiuDirector
  • Baolin MaDirector
  • Yuhao YangDirector
  • Mr. Li-Chun HanIndependent Director
  • Mr. Neuro KaoIndependent Director
  • Mr. Congzhi QiuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Sinew Pharma's SNP-610 targets fatty liver disease treatment with clinical trials underway.
  • SNP-810 offers no hepatotoxicity painkillers in clinical trials for safe use.
  • The company focuses on liver disease treatment drugs with 49 employees in Taipei City.

Weaknesses

  • Sinew Pharma has only 49 employees, limiting R&D capacity in Taipei City.
  • The firm's products are still in clinical trials, delaying market entry.
  • Sinew Pharma's focus on liver disease treatment restricts product diversification.

Opportunities

  • Expanding clinical trials for SNP-610 could lead to market approval in Taiwan.
  • SNP-810's no hepatotoxicity feature may attract global pain medication markets.
  • Growing demand for liver disease treatments in Asia presents new opportunities.

Threats

  • Competition from established pharmaceutical companies in the Health Care sector.
  • Regulatory delays in clinical trials could impact product launch timelines.
  • Market saturation in liver disease treatment drugs may reduce profitability.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.